WHO HIV prophylaxis trial data shows cut in maternal transmission
This article was originally published in Scrip
The WHO-led Kesho Bora study, published online on 14th January in The Lancet, shows that triple antiretroviral therapy is significantly more effective at preventing mother-to-child transmission of HIV than a more standard dual drug treatment. WHO has changed two of its HIV treatment recommendations in line with study’s findings. However, the study coordinator, Dr Isabelle de Vincenzi at the Department of Reproductive Health and Research at WHO told Scrip that the real obstacle to reducing HIV transmission lay not in the drug regime used or even the costs of the drugs but in the capacity of the health systems in sub-Saharan Africa to intervene early in pregnancy, or even before conception.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.